Estrogen/Progesterone Receptor with Interpretation by Immunohistochemistry

Also known as: ERPR IP

Clinical Use

Use

This test aids in the prediction of response to antiestrogen agents for patients with ductal carcinoma in situ (DCIS) and invasive cancers. It evaluates the presence of estrogen and progesterone receptors, which are critical for guiding treatment options in breast cancer therapy.

Special Instructions

Not provided.

Limitations

Specimens fixed for less than 6 hours or greater than 72 hours are unacceptable. Paraffin block with no tumor tissue remaining and specimens with fixation delayed for more than one hour will be rejected. Specimens must be fixed in 10 percent neutral buffered formalin; other fixatives are not acceptable.

Test Details

New York Approved

Methodology

Immunoassay (IHC)

Biomarkers

Estrogen Receptor

Protein

Estrogen Receptor Intensity

Expression • Ordinal Score (e.g., TPS, CPS, H-score)

Progesterone Receptor

Protein

Progesterone Receptor Intensity

Expression • Ordinal Score (e.g., TPS, CPS, H-score)

LOINC Codes

Result Codes

40556-3 - ER Ag Tiss Ql ImStn
14228-1 - ER+ cells NFr Tiss ImStn
10480-2 - ERA+PGRA Ag Tiss Ql ImStn
14230-7 - PR+ cells NFr Tiss ImStn
55229-9 - Immune stain study
94736-6 - Tissue block ID Spec
31208-2 - Specimen source

Result Turnaround Time

2-4 days

Specimen

Tumor Tissue (FFPE)

Volume

Not provided

Minimum Volume

4 slides

Container

Tissue block or 5 unstained, positively charged slides

Collection Instructions

Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue no later than 1 hour after removal from patient. If sending precut slides, do not oven bake.

Storage Instructions

Room temperature or refrigerated. Ship in cooled container during summer months.

Causes for Rejection

Paraffin block with no tumor tissue remaining, fixation delayed over one hour, tissue fixed less than 6 hours or more than 72 hours, decalcified specimens.